Vx Pharma was registered in September 2009 and obtained its first round of venture funding in October 2010, through the generous seed investments of Ms Debra Barron and Ms Nontobeko Jacobs, who became minority shareholders.
Continuing the company’s expansion, Dr Fyvie joined forces with Dr Gil Mahlati and Dr Paul Abrahams in September 2011, making them major strategic shareholders in the business. In December 2011, acknowledging the company’s need to complete its infrastructure build and growth cycle, the Industrial Development Corporation (IDC) of South Africa invested significant venture capital.
The management team of Vx Pharma has secured strategic alliances and projects that have established Vx Pharma as a reputable role player in the world of clinical research:
Vx Pharma acquired the Pretoria-based satellite site operations of Syzygy Clinical Research Services, a service provider that conducts clinical trials at a dedicated site, as well as through the network of practices known as The Intercare Group.
In the pipeline
Vx Pharma is committed to scientifically and ethically sound research to protect their human research participants via targeting AAHRPP accreditation: The Association for the Accreditation of Human Research Protection Programs, Inc. promotes high-quality research through a voluntary peer-driven model to ensure that human research protection programs meet rigorous standards for quality and protection.
Vx Pharma elects to be part of the country’s empowerment landscape through accreditation of Broad-Based Black Economic Empowerment (BBBEE), a growth strategy that aims to integrate all South Africa’s people in an enterprising
way. Vx Pharma is 33 % black owned and is committed to broadening its BEE footprint.